THERAPY DOSSIER · th-ecbf194c5753

Amnion-derived cellular cytokine solution (ACCS)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 4

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00886470 ↗Injury indicationPHASE1/PHASE2terminated

ACCS in 3 regimens vs standard care 0.9% sodium chloride in topical treatment of partial-thickness burns (ST266)

Burns

Enrolment: 16 · Results not recorded

NCT02071199 ↗PHASE1completed

Treatment of human gingivitis with topical ACCS: two-week safety dose-ranging and proof-of-principle trial

Gingivitis

Enrolment: 54 · Results not recorded

NCT02369861 ↗PHASE1completed

ACCS (ST266) eye drops in the treatment of dry eye

Dry Eye Syndrome

Enrolment: 30 · Results not recorded

NCT01714973 ↗PHASE1completed

ACCS (ST266) versus saline sprayed on the breast during radiation therapy for breast cancer

Radiation-induced Dermatitis

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21185550 ↗2010Reported benefit

Individualized, targeted wound treatment based on the tissue bacterial level as a biological marker.

RatWoundSprague-DawleyTopical

Model: Rat chronic/open granulating wounds with varying tissue bacterial load

Topical ACCS accelerated wound healing regardless of bacterial load, with higher application frequency needed at higher tissue bacterial levels.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…